Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial.
about
Improving inflammatory arthritis management through tighter monitoring of patients and the use of innovative electronic toolsThe Changing Face of Clinical Trials in Psoriatic Arthritis.Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders.Defining Low Disease Activity in Systemic Lupus Erythematosus.Economic impact of biologic utilization patterns in patients with psoriatic arthritisThe GOLMePsA study protocol: an investigator-initiated, double-blind, parallel-group, randomised, controlled trial of GOLimumab and methotrexate versus methotrexate in early diagnosed psoriatic arthritis using clinical and whole body MRI outcomesPromoting patient-centred care in psoriatic arthritis: a multidisciplinary European perspective on improving the patient experience.Non-pharmacological and pharmacological interventions in patients with early arthritis: a systematic literature review informing the 2016 update of EULAR recommendations for the management of early arthritis.Persistence of low disease activity after tumour necrosis factor inhibitor (TNFi) discontinuation in patients with psoriatic arthritis.Real-life experience of using conventional disease-modifying anti-rheumatic drugs (DMARDs) in psoriatic arthritis (PsA). Retrospective analysis of the efficacy of methotrexate, sulfasalazine, and leflunomide in PsA in comparison to spondyloarthritidMitigation of disease- and treatment-related risks in patients with psoriatic arthritis.Patterns of Systemic Treatment for Psoriatic Arthritis in the United States: 2004-2015.European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update.Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis.Treating to target in psoriatic arthritis: how to implement in clinical practice.Improving the Management of Psoriatic Arthritis and Axial Spondyloarthritis: Roundtable Discussions with Healthcare Professionals and Patients.Residual disease activity in psoriatic arthritis: discordance between the rheumatologist's opinion and minimal disease activity measurement.Psoriatic arthritis: complexities, comorbidities and implications for the clinic.Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force.Assessing disease activity in psoriasis and psoriatic arthritis: impact on management and therapy.Points to Consider in the Foundation of Multidisciplinary Units for Psoriatic Arthritis: A Delphi Study and a Systematic Review of the Literature.Treatment of psoriatic arthritis with traditional DMARD's and novel therapies: approaches and recommendations.Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations.Therapies of Early, Advanced, and Late Onset Forms of Axial Spondyloarthritis, and the Need for Treat to Target Strategies.Treat to Target in Axial Spondyloarthritis: What Are the Issues?Clinical utility of therapeutic drug monitoring in biological disease modifying anti-rheumatic drug treatment of rheumatic disorders: a systematic narrative review.Real-world validation of the minimal disease activity index in psoriatic arthritis: an analysis from a prospective, observational, biological treatment registry.Performance of screening tools for psoriatic arthritis: a cross-sectional study in primary care.Residual disease activity and treatment adjustments in psoriatic arthritis in current clinical practicePrediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial.Remission in psoriatic arthritis-where are we now?Prevalence and predictors of tumour necrosis factor inhibitor persistence in psoriatic arthritis.Interval between onset of psoriasis and psoriatic arthritis comparing the UK Clinical Practice Research Datalink with a hospital-based cohort.Magnetic resonance imaging (MRI) of feet demonstrates subclinical inflammatory joint disease in cutaneous psoriasis patients without clinical arthritis.Implementation of protocolized tight control and biological dose optimization in daily clinical practice: results of a pilot study.Clinical Features of Psoriatic Arthritis: a Comprehensive Review of Unmet Clinical Needs.Psoriatic arthritis: is it time to treat-to-target or target to treat?Comment on: Residual disease activity in psoriatic arthritis: discordance between the rheumatologist's opinion and minimal disease activity measurement.Focussing on the foot in psoriatic arthritis: pathology and management options.New GRAPPA recommendations for the management of psoriasis and psoriatic arthritis: process, challenges and implementation.
P2860
Q28071252-AED45AF4-15B9-4A40-A71B-68C03B6B3FE0Q30235002-CD910902-EB5F-493B-85B4-4CBEFE122B4DQ30399745-1DE1CBA7-81CE-45C1-9CD1-8F529D36A2A9Q33435736-83F32C9A-8CCA-4B48-BFCA-86ECD9637D36Q33840422-B6AAE861-F22F-4C44-B453-5AC387DA9125Q33916770-5C749156-C7E7-4D16-B02F-DC58B8690D83Q37308871-4A5C6BC9-8031-4CAC-BAA6-5E434E2914EEQ37587409-D8971F2A-E3DF-44ED-87C3-D0EE907AAF80Q37599159-6A5273AD-7BFB-4446-BC75-170E7B7C3F65Q37679286-C4ED671F-B268-4C11-9115-C9A8AC297E49Q37713522-DB5D0E85-64DB-46A8-AF8F-DCBA9E36236FQ38399089-3B8F6BED-59B4-4DEA-8E12-4714548F3503Q38661777-EB611AB0-3BD5-485E-8296-88A97B119334Q38667430-43B99FA7-FF27-49A3-B889-EE42E5857B72Q38670583-1EBCAF40-D958-45D9-B76C-3F68F688E4A0Q38672570-CA0A31AF-C5B4-4E1A-ACC4-0AEC7A2AB846Q38679357-AFF9D760-079E-41BC-AA9E-1C896B1DC7DBQ38688128-3C1048C1-EE80-42AD-ABDB-0DF6985E4F82Q38690324-87C0C2A1-4040-4333-BC31-5112B99E209EQ38710469-E6259686-2396-4A8F-B633-215D1311BFA3Q38809161-200FE7F8-C3C5-4F4C-91B0-2F17BA79DA69Q39003610-AA96EFCD-B44C-417B-A11B-29D6B2C8938CQ39004045-C6208947-74D0-48C6-A167-D192683C6D29Q39135959-4FA46C2E-5F2A-4134-A3CB-36711E1E7B3FQ39225782-4E7527DF-DAC6-4836-BAA6-511EBFF8E11BQ39420995-88759FB8-3CD5-4CC1-97BB-8AB268FB2C77Q40074154-94A4C1B6-7276-47F5-ACA3-EAF2C3E45F5FQ40408596-AD89D39C-7259-420D-8A3E-17D388B8747AQ42374129-81293F24-25DC-4D52-ACFF-4DFCD789743FQ46625937-42B525D6-B3DB-4725-9B73-1FB9DBE0DB9FQ47432586-7B99F5C2-0D8A-4847-8F76-3FD949EB3486Q47595036-B0707BC0-07C8-4D60-AC30-B10FF9BEBACCQ47664380-17595288-07AB-4A6D-AF74-7CCFB768F282Q47800925-A043981F-DE9D-4641-8272-C8EFB66D1DE8Q48035875-002EE7B3-40FA-47D8-BAE2-173A3413F719Q48339070-4EAB22F4-FA32-4902-A725-BD8DF4717E2DQ48620762-0D631E60-E3E4-4DE9-94FD-BAE54F977600Q50067869-79010C43-0CE1-4BE4-A344-99CC57360C07Q50087443-5EEE4673-2AC6-4727-B4B7-1DD4093C8532Q50625266-4BCEC507-1DDB-4D9E-BE26-A1A7F53D6100
P2860
Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 30 September 2015
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Effect of tight control of inf ...... , randomised controlled trial.
@en
Effect of tight control of inf ...... , randomised controlled trial.
@en-gb
Effect of tight control of inf ...... , randomised controlled trial.
@nl
type
label
Effect of tight control of inf ...... , randomised controlled trial.
@en
Effect of tight control of inf ...... , randomised controlled trial.
@en-gb
Effect of tight control of inf ...... , randomised controlled trial.
@nl
prefLabel
Effect of tight control of inf ...... , randomised controlled trial.
@en
Effect of tight control of inf ...... , randomised controlled trial.
@en-gb
Effect of tight control of inf ...... , randomised controlled trial.
@nl
P2093
P2860
P50
P1154
2-s2.0-84955557480
P1433
P1476
Effect of tight control of inf ...... , randomised controlled trial.
@en
P2093
Anna R Moverley
David M Meads
John L O'Dwyer
Lucy McParland
Nuria Navarro-Coy
P2860
P304
P356
10.1016/S0140-6736(15)00347-5
P407
P5530
P577
2015-09-30T00:00:00Z
P6179
1021119784